TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04900467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna
Description: mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderna
Description: mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna
Description: mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
Study: NCT04824274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Morphine 75 mcg will be injected intrathecally during spinal anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham block
Description: Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
Study: NCT05629845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic ultrasound-guided therapy
Description: EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
Study: NCT05102214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX301
Description: A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, HLX301 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX301
Description: A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, HLX301 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX301
Description: A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, HLX301 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
Study: NCT04791514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil
Description: Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
Study: NCT06172621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Associative Plasticity (SCAP)
Description: Paired non-invasive brain and spinal cord stimulation.
Study: NCT05795400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: 10 mg tablets given once daily, per oral use
Study: NCT06172621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Associative Plasticity (SCAP)
Description: Paired non-invasive brain and spinal cord stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper extremity task-oriented exercise
Description: Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.
Study: NCT06219278

Intervention type: DEVICE
Intervention: Profound Matrix
Description: The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
Study: NCT06498869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: This group will be administered ketamine (0.25-0.50 mg/kg)
Study: NCT05895955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraFluvac TF vaccine
Description: The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus\] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip vaccine
Description: Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France.~Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection.
Study: NCT05795400

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet of placebo drug dosed once daily
Study: NCT04884997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab
Description: toripalimab 3mg/kg, Q2w;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: toripalimab 3mg/kg, Q2w;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Injection
Description: Temozolomide 150mg/m2,d1-5,Q4w
Study: NCT05963555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoThor
Description: Following the baseline block (first four weeks), participants will use the NovoThor device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VieLight
Description: Following the baseline block (first four weeks), participants will use the VieLight device 2-3 times per week for 20 minute sessions and may be completed at home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZeroBody
Description: Following the baseline block (first four weeks), participants will use the Zerobody device 2-3 times per week for 20 minute sessions at the WVU Rockefeller Neuroscience Institute.
Study: NCT06109129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXOPULSE Mollii Suit
Description: EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
Study: NCT04954391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed radiofrequency neuromodulation of the suprascapular nerve only
Description: PRF stimulation of the suprascapular nerve under ultrasound navigation in the notch of the scapula using the Cosman G4 apparatus with the introduction of stimulation: sensory: 50 Hz; 1 ms; up to 0.5 V; motor: 2 Hz; 1 ms; voltage - twice the sensory threshold, but not less than 1V; after introduction of 1 ml of 0.75% ropivacaine, PRF is performed: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec. Before removing the cannula, local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg.~Under the US navigation, an RF cannula will be placed sequentially at the axillary nerve in the quadrilateral foramen and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation and local administration of 0.75% ropivacaine 1 ml PRF session imitation lasting 480 sec will be carried out. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed radiofrequency neuromodulation of the suprascapular, axillary, and articular branch of the lateral pectoral nerves
Description: Under ultrasound navigation an RF cannula will be placed sequentially at the suprascapular nerve, at the axillary nerve and at the lateral pectoral nerve. After confirmatory sensory and motor stimulation from RF generator and local administration of 0.75% ropivacaine 1 ml to each nerve, PRF neuromodulation session will be carried out: 42 С, 45V, 2Hz, 20 ms, 1 cycle - 480 sec to each nerve. After that local administration of 0.75% ropivacaine 2 ml, dexamethasone 4 mg will follow to each nerve. The total dose for the entire procedure is ropivacaine 0.75% - 9 ml, dexamethasone 12 mg
Study: NCT05439304

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05630690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL with smart diagnostic handpiece
Description: treatment with IPL following diagnostic with SMART system
Study: NCT05439304

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06292403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
Study: NCT05645705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: OTHER
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LISTERINE Cool Mint Antiseptic Mouthwash
Description: Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
Study: NCT06507982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EWL
Description: the working length determination with EAL method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWL
Description: In this method, an endodontic motor with a built-in EAL that provides continuous feedback during root canal instrumentation and allows clinicians to make real-time adjustments to the WL. Thus, it provides continuous feedback, allowing the clinician to make real-time adjustments. The motor of devices using this method has automatic apical reverse and automatic apical stop operation. In this way, when the tip of the file reaches the apical foramen, the file safely reverses and stops rotating.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RWL
Description: Radiographic method was used for determining the working length
Study: NCT05777876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial deep brain stimulation
Description: A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial deep brain stimulation
Description: A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial deep brain stimulation
Description: A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation
Description: Receive stimulation in the motor cortex stimulation instead of deep brain.
Study: NCT04713644

Intervention type: DRUG
Intervention: Standardized Propofol Administration
Description: Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary

Intervention type: DRUG
Intervention: Standardized Propofol Administration
Description: Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
Study: NCT06003452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surface treatment with Bioactive Glass Air Abrasion
Description: giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surface treatment with Bioactive Glass Air Abrasion
Description: giomer based fissure sealnt will be applied after surface treatment With Bioactive Glass Air Abrasion
Study: NCT05385926

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.
Study: NCT05632913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study: NCT05793424

Intervention type: OTHER
Intervention: Cerebrospinal fluid (CSF) sample and additional blood samples
Description: Lumbar puncture (Spinal Tap) and additional blood samples
Study: NCT04741087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMT-101 (oral)-Dose A
Description: AMT-101 is an orally administered biologic therapeutic, taken once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMT-101 (oral)-Dose B
Description: AMT-101 is an orally administered biologic therapeutic, taken once daily.
Study: NCT05566327

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: De-implementation Bundle
Description: A multicomponent intervention directed at the drivers of low value preoperative testing.~An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing scheduled surgery will be ordered at the discretion of a consulting anaesthesiologist only. Workshops will be delivered to surgical, internal medicine, and anaesthesia divisions. The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies.The clinical departments will commit to supporting the change in policy. Nurses will be coached to feel comfortable calling the anesthesiologist about any preoperative tests ordered, and the PAC nurses will have the authority to cancel tests. Check boxes will be removed from surgeons' and family physicians' order forms to reduce to ease of ordering the tests.
Study: NCT05629845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional endoscopic therapy
Description: conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
Study: NCT06221137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional circumferential supracrestal fiberotomy
Description: The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser circumferential supracrestal fiberotomy
Description: * The amount of tooth that need to be extruded will be measured~* Bonding brackets slot 0,022x0.028 Roth prescription~* piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy~* After 2 days of bonding, local anaesthetic solution will be administrated.~* The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed.
Study: NCT05894889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV infusion
Description: Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion
Study: NCT05110404

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The high-volume HIIT
Description: patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The low-volume HIIT
Description: Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
Study: NCT05861557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Subjects were treated with SBRT radiotherapy (8Gy\*5Fx), after 1 cycle of immunotherapy
Study: NCT05777876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial deep brain stimulation with closed-loop
Description: Non-invasive transcranial deep brain stimulation devices based on closed-loop regulation of EEG can improve the accuracy of treatment.
Study: NCT05645705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Advanced Gum Alcohol
Description: Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Advanced Gum Zero
Description: Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint
Description: Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
Study: NCT05655728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose \[maximum: 1500 mg/day\]).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive treatment of placebo.
Study: NCT06550973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique
Description: Rescue techniques, such as pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique, wire-guided cannulation over a pancreatic stent and transpancreatic biliary sphincterotomy, will be used at the discretion of the endoscopist \[12\]. After deep cannulation, a cholangiogram to better define the characteristics of the stenosis will be done. The stent will then be inserted over a guidewire and deployed across the stenosis. All stents will be fully covered SEMSs or partially covered SEMSs of 10 mm diameter. The length of the stent will be chosen at the discretion of the endoscopist performing the procedure. A prophylactic pancreatic stent will be placed in patients who will be thought to be at high risk of post-procedure pancreatitis at the discretion of the treating endoscopist.